BioGaia announces two major distribution and license agreements in Japan.
M2 EQUITYBITES-December 6, 2016-BioGaia announces two major distribution and license agreements in Japan
(C)2016 M2 COMMUNICATIONS http://www.m2.com
BioGaia AB (STO:BIOGB) on Monday announced the signing of a two new exclusive distributor agreements for Japan, through its Japanese subsidiary, with Nippon Kabaya Ohayo Holdings Inc.
Out of these agreements, the first agreement concerns the exclusive rights to sell probiotic supplements with BioGaia's patented strains of Lactobacillus reuteri at drugstores, supermarkets and similar outlets. Depending on the product category, products will be sold under Kabaya, Ohayo and/or BioGaia brands and the main target segment is adults.
The second agreement is an exclusive license, giving Ohayo Dairy Products the rights to use strains of Lactobacillus reuteri in food, such as drinks and dairy products.
Launches under both these agreements are planned to 2017.
According to the company, these agreements are long term and include exclusivity fees and minimum royalties over the term of the contracts, which will have a substantial effect on BioGaia's Japanese business. Due to confidentiality, the amounts of the fees and the royalties cannot be disclosed.
BioGaia is a Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 90 countries worldwide.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Dec 6, 2016|
|Previous Article:||Investor's board utilises share transfer authorisation.|
|Next Article:||SES announces addition of 4KUNIVERSE Ultra HD Channel to its line-up.|